On behalf of the Free State of Bavaria, BioM Biotech Cluster Development coordinates the Cluster Biotechnology Bavaria. We connect the Bavarian biotech regions, which focus on different biotech sectors, within a large network. Central tasks of BioM are: targeted industry scouting of research projects, technology transfer, networking, SME support, and international connection and marketing of the region. BioM also manages the Munich Biotech Cluster and is the gateway to all bio-pharmaceutical companies and start-ups in the region.
An information portal at www.bio-m.org provides an extensive company database, news updates and a job market. BioM offers a wide range of services for international players looking for business in Bavaria. Awarded Germany´s Leading-Edge Cluster, coordinated by BioM and with a focus on personalized medicine and targeted therapies, the Munich Biotech Cluster is taking drug development into a new dimension.
The innovative, research-driven life science and bio-pharma industry in Bavaria (Southern Germany) is striving not only to keep its status as a leading place for medicine in Europe but also to put Bavaria on the global map. Its R&D companies are focused on personalized medicine with a promising and well-filled drug discovery pipeline. The Bavarian Biotechnology Cluster is supported by innovative companies providing cutting-edge services and internationally acting Clinical Research Organizations.
BioM is the coordinator of the Bavarian Biotechnology Cluster and also of the Munich Biotech Cluster, supporting 410 biotech and pharma companies (185 SMEs) and offering a gateway to the Bavarian biotech industry for partners worldwide. BioM's website (www.bio-m.org) provides an overview on the different activities and stakeholders within the region, including up-to-date news, a searchable database with company profiles, a job forum and much more.
Head of International Affairs
Phone: +49 89 8996790
E-mail: Send message
P4 medicine (predictive, preventive, personalized, participatory) is one of the world's most promising developments for improved, holistic and efficient health care. DigiMed Bayern's goal is to guide Bavaria into this medicine of the future. BioM’s lighthouse P4-medicine project DigiMed Bayern was launched at the end of 2018 with >20 mio € funding by the Bavarian State Ministry of Health and Care. It combines comprehensive datasets of patients diagnosed with atherosclerotic diseases, such as coronary heart disease and stroke, or with genetic risk factors. This dataset will be further enriched with multi-dimensional molecular characterization of associated sample material. For the integrative analysis of the resulting "Big Data", an ethically and legally compliant, highly secure and sustainable IT infrastructure will be designed and implemented. Finally, patients and persons at risk will benefit from advancements in disease risk prediction, targeted prevention, diagnosis and treatment.